Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4EVERUK: Everolimus and Exemestane in ER+ Advanced Breast Cancer
NCT01743560Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2013
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in breast cancer, sponsored by Novartis. Primary endpoints: Overall Response Rate at 48 weeks and Best Overall Response at 48 weeks. Started Jan 2013; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01743560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01743560.